
Corpay Cross-Border成為皇家馬德里俱樂部官方合作夥伴
透過此次合作,皇家馬德里將能夠獲得並使用Corpay Cross Border的創新解決方案,以協助緩解其日常業務需求帶來的外匯風險。
Corpay Cross-Border Solutions行銷長Brad Loder表示:「Corpay Cross-Border團隊很榮幸能成為皇家馬德里的官方合作夥伴——這是全球知名度最高、粉絲最多的運動品牌之一。我們正大力發展Corpay品牌及貨幣風險管理業務,能與全球最成功的足球俱樂部之一合作,讓我們倍感振奮。」
關於Corpay
Corpay, Inc. (NYSE: CPAY)是一家全球性標準普爾500指數企業支付公司,致力於協助企業和消費者以簡單、可控的方式支付費用。Corpay的現代支付解決方案套件可協助客戶更好地管理與車輛相關的費用(如加油和停車)、旅行費用(如酒店預訂)和應付帳款(如向供應商付款),從而為客戶節省時間並最終降低支出。Corpay Cross-Border是指由Corpay, Inc.擁有和經營的一組法律實體。
Corpay – 讓付款變得簡單。如欲瞭解更多資訊,請造訪 www.corpay.com 。
關於皇家馬德里俱樂部
皇家馬德里俱樂部是一家擁有123年歷史的運動實體。它是獲得歐洲足球聯賽冠軍(15次)和歐洲籃球聯賽冠軍(11次)次數最多的俱樂部,並被國際足球總會評選為二十世紀最佳俱樂部。皇家馬德里在全球擁有大量球迷,社群媒體粉絲超過6.2億,根據Brand Finance的資料,皇家馬德里連續三年蟬聯全球最強足球品牌,也是2023-24賽季全球收入最高的足球俱樂部(Deloitte足球俱樂部財富榜)。如欲瞭解有關皇家馬德里俱樂部的更多資訊,請造訪連續七年造訪量最大的足球俱樂部網站: www.realmadrid.com 。
*本文件中的「Corpay」主要指Corpay, Inc.的Cross-Border業務部門(網址: https://www.corpay.com/cross-border );Corpay Cross-Border旗下公司的完整列表請參見此處: https://www.corpay.com/compliance 。
** 須獲得相關Corpay公司的信用與合規核准。
免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Why Roblox (RBLX) Shares Are Soaring Today
July 31 - Roblox Corp. (NYSE:RBLX) shares climbed 15% Thursday morning after delivering a blockbuster second-quarter report, fueled by a surprise hit game and surging user engagement. Warning! GuruFocus has detected 6 Warning Signs with RBLX. The stock also jumped 19% before the opening bell, extending its 205% gain over the past year, far outpacing the Nasdaq 100's 24% rise. The gaming platform's bookings, a key metric Wall Street follows, climbed 51% year over year, smashing analyst estimates of 34% growth. Daily active users jumped 41%, and hours spent on the platform soared 58%. Much of that momentum came from Grow a Garden, a farming simulation created by user BMWLux, which reached 21 billion visits and set a record with 22 million concurrent players in June. Roblox continues to invest heavily in cloud infrastructure to handle massive traffic surges, a strategy that has begun to pay off. While the company posted a GAAP operating loss of $1.1 billion over the past 12 months, it generated $942 million in free cash flow and ended June with $4.7 billion in cash and investments. Deferred revenue swelled to $5.1 billion, giving Roblox a solid foundation to push toward long-term profitability. This article first appeared on GuruFocus.


Business Upturn
31 minutes ago
- Business Upturn
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor 'What This Means' Segment
By GlobeNewswire Published on July 31, 2025, 22:50 IST Access the 'What This Means' segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) ('GRI Bio' or the 'Company'), a biotechnology company advancing an innovative pipeline of Natural Killer T ('NKT') cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor 'What This Means' segment. For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company's recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis ('IPF'). The 'What This Means' segment can be accessed here. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of Natural Killer T ('NKT') cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ('iNKT') cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT ('dNKT') agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.


Bloomberg
31 minutes ago
- Bloomberg
Bloomberg Tech: Figma Goes Public, CEO Field Sets Eyes on Growth
Bloomberg's Caroline Hyde speaks with Figma CEO Dylan Field from the New York Stock Exchange as his company goes public in one of the year's biggest IPOs. Plus, Qualcomm CEO Cristiano Amon joins Bloomberg's Ed Ludlow to discuss how the company is adapting to declines in handset demand. And Arm CEO Rene Haas says the company made a conscious decision to invest heavily in the previous quarter.